Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.
Provide a brief overview of our therapy options in metastatic colorectal cancer that has progressed after FOLFOX/FOLFIRI.
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
October 9th 2025Surgeons are more likely to perform opportunistic salpingectomy when their peers have done so, underscoring the impact of physician networks in ovarian cancer prevention.
Read More
Discharge Timing and Associations With Outcomes Following Heart Failure Hospitalization
October 9th 2025A retrospective multicenter study found that patients with heart failure discharged by noon had higher short- and long-term mortality and increased early readmission rates compared with afternoon discharges.
Read More
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
October 9th 2025Surgeons are more likely to perform opportunistic salpingectomy when their peers have done so, underscoring the impact of physician networks in ovarian cancer prevention.
Read More
Discharge Timing and Associations With Outcomes Following Heart Failure Hospitalization
October 9th 2025A retrospective multicenter study found that patients with heart failure discharged by noon had higher short- and long-term mortality and increased early readmission rates compared with afternoon discharges.
Read More
2 Commerce Drive
Cranbury, NJ 08512